Helius Medical Technologies Inc Class A Stock

$0.40

2.44% yesterday

Nasdaq, Apr 03, 10:07 pm CET

ISIN

US42328V5049

Symbol

HSDT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Helius Medical Technologies Inc Class A Stock price

$0.40

-489.60 99.92% 5Y

Nasdaq, Closing price Thu, Apr 03 2025

-0.01 2.44%

ISIN

US42328V5049

Symbol

HSDT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$2.45m
Enterprise Value	$1.37m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	2.63
P/S ratio (TTM) P/S ratio	4.71
P/B ratio (TTM) P/B ratio	1.41
Revenue growth (TTM) Revenue growth	-19.25%
Revenue (TTM) Revenue	$520.00k
EBIT (operating result TTM) EBIT	$-13.86m
Free Cash Flow (TTM) Free Cash Flow	$-11.05m
Cash position	$1.09m
EPS (TTM) EPS	$-5.76
P/E forward	negative
P/S forward	4.80
EV/Sales forward	2.69
Short interest	1.18%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Helius Medical Technologies Inc Class A Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Helius Medical Technologies Inc Class A:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Helius Medical Technologies Inc Class A:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Helius Medical Technologies Inc Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.52 0.52	19% 19% 100%
- Direct Costs	0.61 0.61	13% 13% 117%
Gross Profit	-0.09 -0.09	50% 50% -17%
- Selling and Administrative Expenses	10 10	11% 11% 1,935%
- Research and Development Expense	3.66 3.66	24% 24% 704%
EBITDA	-14 -14	14% 14% -2,654%
- Depreciation and Amortization	0.06 0.06	70% 70% 12%
EBIT (Operating Income) EBIT	-14 -14	13% 13% -2,666%
Net Profit	-12 -12	33% 33% -2,258%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Helius Medical Technologies Inc Class A Stock News

Neutral

GlobeNewsWire

●

22 days ago

Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary

--Revelation Neuro, Inc. is focused on advancing development of a Non-Implantable Artificial Intelligence (“AI”) Powered BCI Technology-- --Helius' existing IP portfolio and extensive data warehouse provides a solid foundation for AI algorithm development-- --Helius to Present at the 37 th Annual ROTH Conference on Monday, March 17 at 12:00pm PT-- NEWTOWN, Pa., March 13, 2025 (GLOBE NEWSWIRE) -...

Neutral

GlobeNewsWire

●

24 days ago

Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

--Anthem Blue Cross Blue Shield approves claim for PoNS Device at out-of-network adjusted list price-- --Provides further validation of PoNS pricing-- NEWTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, to...

Neutral

GlobeNewsWire

●

2 months ago

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

--PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy on gait deficit improvement in people with Multiple Sclerosis-- --Statistically significant findings in DGI (Dynamic Gait Index) during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol showing a total mean improvement of 5.00 (4.1 to 5.9, p

More Helius Medical Technologies Inc Class A News

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Head office	United States
CEO	Dane Andreeff
Employees	21
Founded	2014
Website	www.heliusmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now